Torbenson Michael, Thomas David L
Department of Pathology, Division of Gastrointestinal and Hepatic Pathology, Johns Hopkins Hospital, Baltimore, MD, USA.
Lancet Infect Dis. 2002 Aug;2(8):479-86. doi: 10.1016/s1473-3099(02)00345-6.
Worldwide, chronic hepatitis B virus (HBV) infection is the primary cause of cirrhosis and hepatocellular carcinoma and is one of the ten leading causes of death. Traditionally, people with chronic HBV infection have been identified with blood tests for HBV antigens and antibodies. Recently, another group of patients with chronic HBV infection has been identified by sensitive, molecular testing for HBV DNA. Members of this group are often referred to as having occult hepatitis B because they are HBV-DNA positive, but hepatitis B surface antigen negative. Occult hepatitis B occurs in a number of clinical settings. In this review, we examine occult hepatitis B in people co-infected with hepatitis C, in whom occult hepatitis B has been associated with advanced fibrosis and diminished response to interferon alpha. Although much more research is needed, existing reports justify a heightened awareness of the medical importance and means of testing for occult hepatitis B.
在全球范围内,慢性乙型肝炎病毒(HBV)感染是肝硬化和肝细胞癌的主要病因,也是十大主要死因之一。传统上,慢性HBV感染者是通过检测血液中的HBV抗原和抗体来确定的。最近,另一组慢性HBV感染者是通过对HBV DNA进行敏感的分子检测确定的。这组患者常被称为隐匿性乙型肝炎,因为他们HBV DNA呈阳性,但乙肝表面抗原呈阴性。隐匿性乙型肝炎发生在多种临床情况下。在本综述中,我们研究了丙型肝炎合并感染人群中的隐匿性乙型肝炎,在这些人群中,隐匿性乙型肝炎与肝纤维化进展和对α干扰素反应减弱有关。尽管还需要更多的研究,但现有报告证明有必要提高对隐匿性乙型肝炎的医学重要性和检测方法的认识。